

July 17, 2018

BSE Limited

1st Floor, P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated July 17, 2018 titled “Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP.”


The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking You,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP

Ahmedabad, 17 July, 2018

Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate Topical Solution USP (Cleocin T), 1%. Clindamycin is an antibiotic which works by stopping the growth of bacteria. It is used to treat acne and helps to decrease the number of acne lesions. It will be manufactured at group's Topical manufacturing facility at Ahmedabad.

In line with this, the group now has 204 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 22,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
